Clovis Oncology, Inc. (CLVS)
| Market Cap | 577.15M |
| Revenue (ttm) | 160.53M |
| Net Income (ttm) | -369.76M |
| Shares Out | 88.26M |
| EPS (ttm) | -5.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $5.58 |
| Previous Close | $5.58 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 5.96 |
| Day's Range | 5.57 - 5.98 |
| Day's Volume | 5,269,749 |
| 52-Week Range | 3.77 - 11.00 |
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended Dec...
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to ...
Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoin...
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.5
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2020 Results - Earnings Call Transcript
Clovis (CLVS) delivered earnings and revenue surprises of 11.88% and -8.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company's clin...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S...
Despite an almost 60% rise since the March 23 lows of this year, at the current price of around $6 per share, we believe Clovis Oncology stock has more room for growth. CLVS stock has rallied ...
BOULDER, Colo.--(BUSINESS WIRE)--New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Present at the H.C.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, mCRPC
BOULDER, Colo.--(BUSINESS WIRE)--JCO Publishes Additional Data from CLVS TRITON2 Clinical Trial Evaluating Rubraca® for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2020 Results - Earnings Call Transcript
Clovis (CLVS) delivered earnings and revenue surprises of -8.82% and -10.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces Second Quarter 2020 Operating Results
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in.
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc.
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to...
Clovis (CLVS) is developing Rubraca as monotherapy as well as in combination with Bristol-Myers' Opdivo as first-line maintenance treatment for ovarian cancer in the phase III ATHENA study.
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
Clovis Oncology: You Should Embrace Volatility To Enjoy Profitability
Clovis Oncology Inc. (CLVS) CEO Patrick Mahaffy has made it clear he wants to sell the Boulder, Colorado-based biotech, which focuses on developing cancer drugs.
Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday. Late Monday, the company announced a common stock offering of $85 million.
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
Rubraca is the first PARP inhibitor approved for prostate cancer.
Clovis Oncology, Inc. (NASDAQ: CLVS) shares traded higher on Friday afternoon after the company announced the FDA approved its Rubraca tablets for the treatment of adult patients with a delete...
Apple, the S&P 500 ETF, Clovis Oncology, Spirit Airlines and Wells Fargo were our top stock trades to watch going into Thursday.
Clovis Oncology's stock reversed course last month.
Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.
Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues.
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2020 Results - Earnings Call Transcript
Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.
About CLVS
Clovis Oncology, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, a... [Read more...]
| Industry Biotechnology | IPO Date Nov 16, 2011 |
| CEO Patrick Mahaffy | Employees 484 |
| Stock Exchange NASDAQ | Ticker Symbol CLVS |
Financial Performance
In 2019, CLVS's revenue was $143.01 million, an increase of 49.92% compared to the previous year's $95.39 million. Losses were -$400.42 million, 8.81% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for CLVS stock is "Hold." The 12-month stock price forecast is 7.33, which is an increase of 31.36% from the latest price.